Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer

NCT ID: NCT00464646

Last Updated: 2021-10-25

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 105 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2007-05-31
• Study Completion Date: 2014-05-31

Brief Summary

The main purpose is to learn if adding bevacizumab to standard chemotherapy and trastuzumab to treat HER2-positive breast cancer will affect heart function. This study will evaluate:

• How bevacizumab, given with chemotherapy, and then bevacizumab given with trastuzumab after surgery, will affect breast tumors
• Side effects from adding bevacizumab to chemotherapy and trastuzumab
• Whether adding bevacizumab to chemotherapy and trastuzumab for breast cancer will affect the heart
• If receiving bevacizumab will have any effect on how patients recover from surgery

Detailed Description

NSABP FB-5 is a Phase II study for women with HER2-positive invasive breast cancer evaluating a regimen of epirubicin plus cyclophosphamide followed by docetaxel plus trastuzumab and bevacizumab in two patient cohorts:

• Cohort A: Women with unresected locally advanced breast cancer (clinical Stage IIIA, IIIB, and IIIC)
• Cohort B: Women with resected pN2 or pN3 (pathologic Stage III) breast cancer.

The primary aims of the study are to determine the rate of cardiac events for all patients and the pCR rate in the breast and axillary lymph nodes for Cohort A. Cardiac events will be defined as NYHA Class III/IV congestive heart failure and cardiac death. For Cohort A, secondary aims of the study include determining the rate of pCR in the breast and the cCR rate following the neoadjuvant therapy. The secondary aims also include determining the value of the regimen in improving 5-year RFS and 5-year OS and determining the non-cardiac toxicities of the regimen in all patients.

Patients in Cohort A will receive neoadjuvant therapy consisting of epirubicin plus cyclophosphamide (EC) every 21 days for 4 cycles plus bevacizumab given on Day 1 of Cycle 4 only, followed by docetaxel every 21 days for 4 cycles plus bevacizumab every 21 days for the initial 3 cycles. Patients will also receive weekly trastuzumab beginning with the first cycle of docetaxel and continuing until 1-7 days before surgery. Patients will then have breast surgery (lumpectomy or mastectomy) with axillary staging. Approximately 4-6 weeks following surgery, bevacizumab and trastuzumab will resume and continue every 3 weeks for 13 doses to complete one year of targeted therapy.

Patients in Cohort B will receive adjuvant therapy consisting of EC every 21 days for 4 cycles followed by docetaxel every 21 days for 4 cycles. Beginning with the first cycle of docetaxel, patients will also receive bevacizumab every 21 days for 4 cycles and weekly trastuzumab until 3 weeks after the last docetaxel dose. Beginning 3 weeks after the last dose of docetaxel, both bevacizumab and trastuzumab will then be given every 3 weeks for 13 doses to complete 1 year of targeted therapy.

Cardiac monitoring will be conducted for both cohorts. For Cohort A, LVEF assessments will be conducted at baseline, post-EC, 2-4 weeks following surgery (about 6 months from study entry), and 9, 12, 15, and 18 months from study entry. For Cohort B, LVEF assessments will be conducted at baseline, post-EC, and 6, 9, 12, 15, and 18 months from study entry. The preferred method for LVEF assessment is 2-D echocardiogram; however, LVEF assessment by MUGA scan is permitted.

Patient follow-up will continue for 5 years following study entry.

The FB-5 sample size is 105 patients.

Conditions

Breast Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

1

• Cohort A: Women with unresected locally advanced breast cancer (clinical Stage IIIA, IIIB, and IIIC)
• Cohort B: Women with resected pN2 or pN3 (pathologic Stage III) breast cancer

Group Type: EXPERIMENTAL

Epirubicin

Intervention Type: DRUG

Both Cohorts: Epirubicin 90 mg/m2 IV every 21 days x 4 cycles

Cyclophosphamide

Intervention Type: DRUG

Both Cohorts: Cyclophosphamide 600 mg/m2 IV every 21 days x 4 cycles

Docetaxel

Intervention Type: DRUG

Both Cohorts: Docetaxel 100 mg/m2 IV on Day 1 every 21 days x 4 cycles

Trastuzumab

Intervention Type: DRUG

Cohort A: Pre-op therapy - 4 mg/kg IV first dose, then subsequent doses at 2 mg/kg IV weekly (16+ weeks) until 1-7 days prior to surgery. Post-operative therapy (beginning no sooner than 28 days after surgery and continuing every 3 weeks x 13 doses) - 8 mg/kg IV first post-op dose, then subsequent doses at 6 mg/kg IV

Cohort B: 4 mg/kg IV first dose, then subsequent doses at 2 mg/kg IV weekly on days 1, 8, and 15. Three (3) weeks after last dose of docetaxel, 6 mg/kg IV and continuing every 3 weeks x 13 doses

Bevacizumab

Intervention Type: DRUG

Cohort A: Cycles 1-4, 15 mg/kg IV on day 1 of cycle 4 only; Cycles 5-7, 15 mg/kg IV on day 1 every 21 days x 3 cycles; post-operative therapy (beginning no sooner than 28 days after surgery), 15 mg/kg IV every 3 weeks x 13 doses

Cohort B: Cycles 5-8, 15 mg/kg IV on day 1 every 21 days x 4 cycles; beginning 3 weeks after last dose of docetaxel, 15 mg/kg IV every 3 weeks x 13 doses

Interventions

Epirubicin

Both Cohorts: Epirubicin 90 mg/m2 IV every 21 days x 4 cycles

Intervention Type: DRUG

Cyclophosphamide

Both Cohorts: Cyclophosphamide 600 mg/m2 IV every 21 days x 4 cycles

Intervention Type: DRUG

Docetaxel

Both Cohorts: Docetaxel 100 mg/m2 IV on Day 1 every 21 days x 4 cycles

Intervention Type: DRUG

Trastuzumab

Cohort A: Pre-op therapy - 4 mg/kg IV first dose, then subsequent doses at 2 mg/kg IV weekly (16+ weeks) until 1-7 days prior to surgery. Post-operative therapy (beginning no sooner than 28 days after surgery and continuing every 3 weeks x 13 doses) - 8 mg/kg IV first post-op dose, then subsequent doses at 6 mg/kg IV

Cohort B: 4 mg/kg IV first dose, then subsequent doses at 2 mg/kg IV weekly on days 1, 8, and 15. Three (3) weeks after last dose of docetaxel, 6 mg/kg IV and continuing every 3 weeks x 13 doses

Intervention Type: DRUG

Bevacizumab

Cohort A: Cycles 1-4, 15 mg/kg IV on day 1 of cycle 4 only; Cycles 5-7, 15 mg/kg IV on day 1 every 21 days x 3 cycles; post-operative therapy (beginning no sooner than 28 days after surgery), 15 mg/kg IV every 3 weeks x 13 doses

Cohort B: Cycles 5-8, 15 mg/kg IV on day 1 every 21 days x 4 cycles; beginning 3 weeks after last dose of docetaxel, 15 mg/kg IV every 3 weeks x 13 doses

Intervention Type: DRUG

Other Intervention Names

Ellence; Taxotere; Herceptin; Avastin

Eligibility Criteria

Inclusion Criteria

Conditions for eligibility for patients with LABC (Cohort A):

• The diagnosis of invasive adenocarcinoma of the breast must have been made by core needle biopsy or limited incisional biopsy.
• Patients must have clinical Stage IIIA, IIIB, or IIIC disease with a mass in the breast or axilla that is greater than or equal to 2.0 cm measured by clinical exam, unless the patient has inflammatory breast carcinoma, in which case measurable disease is not required.

Conditions for eligibility for patients with resected Stage III breast cancer (Cohort B)

• Patients must have undergone either a total mastectomy or a lumpectomy.
• Patients must have completed one of the following procedures for evaluation of pathologic nodal status.

• Sentinel lymphadenectomy followed by removal of additional non-sentinel lymph nodes, or
• Axillary lymphadenectomy without SN isolation procedure.
• The interval between the last surgery (for breast cancer treatment or staging) and study entry must be no more than 84 days.
• By pathologic evaluation, ipsilateral nodes must be pN2 or pN3.
• For patients who undergo lumpectomy, the margins of the resected specimen must be histologically free of invasive tumor and DCIS as determined by the local pathologist. If pathologic examination demonstrates tumor at the line of resection, additional operative procedures may be performed to obtain clear margins. If tumor is still present at the resected margin after re-excision(s), the patient must undergo total mastectomy to be eligible. (Patients with margins positive for LCIS are eligible without additional resection.)
• For patients who undergo mastectomy, margins must be free of gross residual tumor. Patients with microscopic positive margins are eligible.

Conditions for patient eligibility (ALL patients)

• The patient must have consented to participate and must have signed and dated an IRB-approved consent form that conforms to federal and institutional guidelines.
• Patients must be female.
• The patient must be greater than or equal to 18 years old.
• The patient's ECOG performance status must be 0 or 1.
• The tumor must be invasive adenocarcinoma of the breast on histologic examination.
• The breast cancer must be determined to be HER2-positive prior to study entry. Assays performed using FISH require gene amplification. Assays using IHC require a strongly positive (3+) staining score.
• At the time of study entry, blood counts must meet the following criteria:

• Absolute neutrophil count (ANC) must be greater than/equal to 1200/mm3.
• Platelet count must be greater than/equal to 100,000/mm3.
• Hemoglobin must be greater than/equal to 10 g/dL.
• The following criteria for evidence of adequate hepatic function must be met:

• total bilirubin must be less than/equal to ULN for the lab unless the patient has a grade 1 bilirubin elevation (greater than ULN to 1.5 x ULN) due to Gilbert's disease or similar syndrome involving slow conjugation of bilirubin; and
• alkaline phosphatase must be less than 2.5 x ULN for the lab; and
• AST must be less than/equal to 1.5 x ULN for the lab.
• Alkaline phosphatase and AST may not both be greater than the ULN. For example, if the alkaline phosphatase is greater than the ULN but less than/equal to 2.5 x ULN, then the AST must be less than/equal to the ULN. If the AST is greater than the ULN but less than/equal to 1.5 x ULN, then the alkaline phosphatase must be less than/equal to ULN.
• Patients with AST or alkaline phosphatase greater than ULN are eligible for inclusion in the study if liver imaging (CT, MRI, or PET scan) does not demonstrate metastatic disease, and has adequate hepatic function.
• Patients with either skeletal pain or alkaline phosphatase that is greater than ULN but less than/equal to 2.5 x ULN are eligible for inclusion in the study if a bone scan or PET scan does not demonstrate metastatic disease. Patients with suspicious findings on bone scan or PET scan are eligible if suspicious findings are confirmed as benign by x-ray, MRI, or biopsy.
• Serum creatinine less than/equal to ULN for the lab.
• Urine protein/creatinine (UPC) ratio must be less than 1.0.
• All patients must have their LVEF assessed by 2-D echocardiogram within 3 months prior to study entry. (MUGA scan may be substituted for 2-D echocardiogram based on institutional preferences.) The LVEF must be greater than/equal to 55% regardless of the institution's LLN.
• Note: Since the pre-entry LVEF serves as the baseline for comparing subsequent LVEF assessments to determine if trastuzumab and bevacizumab therapy can be administered, it is critical that this baseline study be an accurate assessment of the patient's LVEF. If the baseline LVEF is greater than 65%, the investigator is encouraged to have the accuracy of the initial LVEF result confirmed and to consider repeating the study if the accuracy is uncertain.

Exclusion Criteria

Conditions for patient ineligibility (Cohort A)

• FNA alone to diagnose the primary tumor.
• Surgical axillary staging procedure prior to study entry. (Procedures that are permitted include: 1) FNA or core biopsy of an axillary node for any patient, and 2) although not recommended, a pre-neoadjuvant therapy SN biopsy for patients with clinically negative axillary nodes.

Condition for patient ineligibility (Cohort B)

• Breast reconstruction using tissue expanders or implants at the time of mastectomy.

Conditions for patient ineligibility (ALL patients)

• Definitive clinical or radiologic evidence of metastatic disease.
• Synchronous bilateral invasive breast cancer.
• History of ipsilateral or contralateral invasive breast cancer regardless of treatment or ipsilateral DCIS treated with RT.
• History of non-breast malignancies within the 5 years prior to study entry. Patients with the following cancers are eligible if diagnosed and treated within the previous 5 years: carcinoma in situ of the cervix, carcinoma in situ of the colon, melanoma in situ, and basal cell and squamous cell carcinoma of the skin.
• Prior therapy with anthracyclines, taxanes, trastuzumab, or bevacizumab for any malignancy.
• Treatment including RT, chemotherapy, and/or targeted therapy, administered for the currently diagnosed breast cancer prior to study entry.
• Continued therapy with any hormonal agent such as raloxifene, tamoxifen, or other SERM. (Patients are eligible if these medications are discontinued prior to study entry.)
• Any sex hormonal therapy, e.g., birth control pills, ovarian hormone replacement therapy, etc. These patients are eligible if this therapy is discontinued prior to study entry. (Women of reproductive potential must agree to use an effective non-hormonal method of contraception during study therapy and for at least 6 months after completion of targeted therapy.)
• Cardiac disease that would preclude the use of the drugs included in the FB-5 treatment regimen. This includes but is not confined to:

• Active cardiac disease: angina pectoris that requires the use of anti-anginal medication; ventricular arrhythmias except for benign premature ventricular contractions controlled by medication; supraventricular and nodal arrhythmias requiring a pacemaker or not controlled with medication; conduction abnormality requiring a pacemaker; and clinically significant valvular disease.
• History of cardiac disease: myocardial infarction documented by elevated cardiac enzymes or persistent regional wall abnormalities on assessment of LV function; documented CHF; or documented cardiomyopathy.
• Uncontrolled hypertension defined as systolic BP greater than 150 mmHg or diastolic BP greater han 90 mmHg, with or without anti-hypertensive medication. Patients with initial BP elevations are eligible if initiation or adjustment of BP medication lowers pressure to meet entry criteria.
• History of hypertensive crisis or hypertensive encephalopathy.
• History of TIA or CVA.
• History of other arterial thrombotic event within 12 months before study entry.
• Symptomatic peripheral vascular disease.
• Any significant bleeding within 6 months before study entry, exclusive of menorrhagia in premenopausal women.
• Serious or non-healing wound, skin ulcers, or bone fracture.
• Gastroduodenal ulcer(s) determined by endoscopy to be active.
• History of GI perforation, abdominal fistulae, or intra-abdominal abscess.
• Anticipation of need for major surgical procedures (other than the breast surgery required for patients in Cohort A) during study therapy and for at least 3 months following completion of bevacizumab.
• Known bleeding diathesis, coagulopathy, or requirement for therapeutic doses of coumadin.
• Other nonmalignant systemic disease that would preclude the patient from receiving study treatment or would prevent required follow-up.
• Sensory/motor neuropathy greater than/equal to grade 2, as defined by the NCI's CTCAE v3.0.
• Conditions that would prohibit administration of corticosteroids.
• History of hypersensitivity reaction to drugs formulated with polysorbate 80.
• Pregnancy or lactation at the time of study entry. (Note: Pregnancy testing should be performed according to institutional standards for women of child-bearing potential.)
• Use of any investigational agent within 4 weeks prior to enrollment in the study.
• Psychiatric or addictive disorders or other conditions that, in the opinion of the investigator, would preclude the patient from meeting the study requirements.

• Minimum Eligible Age: 18 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

Genentech, Inc.

INDUSTRY

Sponsor Role: collaborator

International Drug Development Institute

OTHER

Sponsor Role: collaborator

NSABP Foundation Inc

NETWORK

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Norman Wolmark, MD

Role: PRINCIPAL_INVESTIGATOR

NSABP Foundation Inc

Locations

Clearview Cancer Institute- Huntsville

Huntsville, Alabama, United States

Kaiser Permanente-San Diego

San Diego, California, United States

Kaiser Permanente-Vallejo

Vallejo, California, United States

CCOP, Colorado Cancer Research Program, Inc.

Denver, Colorado, United States

Baptist Regional Cancer Institute

Jacksonville, Florida, United States

Rush University Medical Center

Chicago, Illinois, United States

CCOP, Central Illinois

Springfield, Illinois, United States

CCOP, Northern Indiana Cancer Research Consortium

South Bend, Indiana, United States

University of Iowa

Iowa City, Iowa, United States

NortonHealtcare Inc.

Louisville, Kentucky, United States

CCOP, Grand Rapids Clnical Oncology Program

Grand Rapids, Michigan, United States

CCOP, Michigan Cancer Research Consortium

Grosse Pointe Woods, Michigan, United States

CCOP, Kalamazoo, MI

Kalamazoo, Michigan, United States

Michigan State University - Breslin Cancer Center

Lansing, Michigan, United States

CCOP, Metro-Minnesota

Minneapolis, Minnesota, United States

CCOP, Cancer Research for the Ozarks

Springfield, Missouri, United States

Cancer Institute of New Jersey

New Brunswick, New Jersey, United States

University Hospital and Medical Center - SUNY

Stony Brook, New York, United States

CCOP, Southeast Cancer Control Consortium

Charlotte, North Carolina, United States

East Carolina University

Greenville, North Carolina, United States

Aultman Hospital

Canton, Ohio, United States

Case Western Reserve/University Hospitals-Ireland Cancer Cntr.

Cleveland, Ohio, United States

CCOP, Dayton, OH

Dayton, Ohio, United States

CCOP, Columbia River Oncology

Portland, Oregon, United States

Kimmel Cancer Center at Jefferson

Philadelphia, Pennsylvania, United States

Albert Einstein Healthcare Network

Philadelphia, Pennsylvania, United States

Allegheny General Hospital/Allegheny-Singer Research Institute

Pittsburgh, Pennsylvania, United States

NSABP Foundation, Inc.

Pittsburgh, Pennsylvania, United States

University of Pittsburgh

Pittsburgh, Pennsylvania, United States

Mercy Hospital

Scranton, Pennsylvania, United States

CCOP, Upstate Carolina

Spartanburg, South Carolina, United States

Joe Arrington Cancer Research & Treatment Center

Lubbock, Texas, United States

CCOP, Scott and White Memorial Hospital

Temple, Texas, United States

MBCCOP, Virginia Commonwealth University

Richmond, Virginia, United States

CCOP, Marshfield Clinic

Marshfield, Wisconsin, United States

University of Montreal Hospital Group

Montreal, Quebec, Canada

Countries

United States; Canada

Other Identifiers

NSABP FB-5

Identifier Type: -

Identifier Source: org_study_id